# Cerebrospinal Fluid Neurotransmitters, Pterins, Folates and Amino Acids in Paediatric Onset Epilepsies: A Tertiary Centre Retrospective Cohort Study

**Authors:** Mario Mastrangelo, Claudia Carducci, Filippo Manti, Giacomina Ricciardi, Rossella Bove, Francesco Pisani, Vincenzo Leuzzi

PMC · DOI: 10.3390/children12111514 · Children · 2025-11-09

## TL;DR

This study examines cerebrospinal fluid metabolites in children with epilepsy to understand their clinical significance and associations with seizure patterns and comorbidities.

## Contribution

The study provides new insights into how CSF metabolite levels correlate with epilepsy severity, comorbid conditions, and medication use in pediatric patients.

## Key findings

- Higher seizure frequency correlates with elevated CSF homovanillic acid and its ratio to 5-hydroxyindolacetic acid.
- Lower levels of specific metabolites like 3-O-methyldopa and biopterin are linked to neurodevelopmental and movement disorders.
- Antiseizure polytherapy is associated with significantly lower CSF glutamine levels.

## Abstract

Objectives: To investigate the clinical value of cerebrospinal fluid (CSF) testing for biogenic amine, pterins, amino acids, and folates in paediatric onset epilepsies. Methods: Retrospective clinical and biochemical phenotyping of patients with epilepsy who underwent diagnostic CSF measurement of monoamine neurotransmitters, pterins, folates, and amino acids between 2009 and 2022. Results: The studied cohort included 123 patients with epilepsy (mean age at the procedure: 4.54 ± 3.65 years). The diagnostic yield for primary neurotransmitter disorders was 1.68% and zero for inherited amino acid and folate metabolism disorders. Patients with higher seizure frequency showed higher levels of CSF homovanillic acid (HVA) and HVA/5-hydroxyindolacetic acid (5HIAA) ratio. Lower levels of 3-O-methyldopa (3-OMD) were found in patients with co-occurring neurodevelopmental disorders, and lower levels of biopterin, 3-methoxy-4-hydroxyphenylglycol (3-MHPG) and 5-methyltetrahydrofolate (5-MTHF) in those with movement disorders. Significantly lower CSF glutamine levels were found in patients receiving antiseizure medications as polytherapy. Patients with a history of status epilepticus had significantly lower levels of CSF aspartic acid, glycine, leucine, ornithine, and valine, and higher levels of CSF serine. Conclusions: CSF analysis disclosed differences in the concentrations of various metabolites that might be related to the severity of the epilepsy, the presence of comorbid conditions, and medications.

## Linked entities

- **Chemicals:** homovanillic acid (PubChem CID 1738), 5-hydroxyindolacetic acid (PubChem CID 1826), 3-O-methyldopa (PubChem CID 1670), biopterin (PubChem CID 135403659), 3-methoxy-4-hydroxyphenylglycol (PubChem CID 10805), 5-methyltetrahydrofolate (PubChem CID 135398561), glutamine (PubChem CID 738), aspartic acid (PubChem CID 424), glycine (PubChem CID 750), leucine (PubChem CID 857), ornithine (PubChem CID 389), valine (PubChem CID 1182), serine (PubChem CID 5951)
- **Diseases:** epilepsy (MONDO:0005027), movement disorders (MONDO:0005395)

## Full-text entities

- **Diseases:** movement disorders (MESH:D009069), neurodevelopmental disorders (MESH:D002658), inherited amino acid and folate metabolism disorders (MESH:D000592), status epilepticus (MESH:D013226), Epilepsies (MESH:D004827), neurotransmitter disorders (MESH:D009358), seizure (MESH:D012640)
- **Chemicals:** glycine (MESH:D005998), valine (MESH:D014633), 5-MTHF (MESH:C005984), Amino Acids (MESH:D000596), 3-MHPG (MESH:D008734), 5-hydroxyindolacetic acid (-), serine (MESH:D012694), leucine (MESH:D007930), HVA (MESH:D006719), ornithine (MESH:D009952), Folates (MESH:D005492), glutamine (MESH:D005973), biopterin (MESH:D001708), Pterins (MESH:D011622), biogenic amine (MESH:D001679), 3-O-methyldopa (MESH:C008404), aspartic acid (MESH:D001224)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12651606/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12651606/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12651606/full.md

---
Source: https://tomesphere.com/paper/PMC12651606